Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209235 · ClinicalTrials.gov registry record · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
A NA study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism Type 1A, sponsored by Connecticut Children's Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT00209235 is a NA study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism Type 1A that is actively recruiting participants, run by Connecticut Children's Medical Center. The registered enrollment target is 600 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00209235, a NA study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism Type 1A, is actively recruiting participants, sponsored by Connecticut Children's Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1A who are found to be growth hormone deficient (under R01 FD002568, IND 67148, which ended); those who are growth hormone sufficient and were found to have a positive clinical response to growth hormone in a prior clinical trial (under R01 FD00FD003409, IND 67148, which ended); or those who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD \[R01 FD003409 (which has ended) and R01 FD002568 (which has ended)\] Cognitive/behavior: NICHD R21 HD078864 (which has ended)
Conditions Studied
Interventions
- BEHAVIORAL Neurocognitive and psychosocial testing
Study Locations (1)
Connecticut
- Connecticut Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2003-01 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00209235
The ClinicalTrials.gov registry entry for NCT00209235 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connecticut Children's Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Albright Hereditary Osteodystrophy appearing as the primary indexed condition, and to 1 intervention - of which Neurocognitive and psychosocial testing is the first listed.
NCT00209235 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00209235 about?
NCT00209235 is a clinical study titled "Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments". We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients wit...
What is the current status of trial NCT00209235?
This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2003-01. Estimated completion is 2030-12.
What conditions does trial NCT00209235 study?
This clinical trial studies the following conditions: Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism Type 1A, Pseudopseudohypoparathyroidism.
What interventions are being tested in trial NCT00209235?
The interventions under investigation include: Neurocognitive and psychosocial testing (BEHAVIORAL).
Who is sponsoring clinical trial NCT00209235?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00209235 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Albright Hereditary Osteodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Albright Hereditary Osteodystrophy
All registered trials for this condition
Pseudohypoparathyroidism Type 1A
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.